Fulltext

The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600

Massi, D. ; Brusa, D. ; Merelli, B. ; Falcone, C. ; Xue, G. ; Carobbio, A. ; Nassini, R. ; Baroni, G. ; Tamborini, E. ; Cattaneo, L. ; Audrito, V. ; Deaglio, S. ; Mandalà, M.

In: Annals of Oncology, 2015, vol. 26, no. 9, p. 1980-1987

Zum persönliche Liste hinzufügen
    Titel
    • The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600
    Autor
    • Massi, D.. Division of Pathological Anatomy, Department of Surgery and Translational Medicine, University of Florence, Florence
    • Brusa, D.. Human Genetics Foundation (HuGeF), Turin
    • Merelli, B.. Unit of Medical Oncology, Department of Oncology and Hematology, Papa Giovanni XXIII Hospital, Bergamo
    • Falcone, C.. Research Foundation, Papa Giovanni XXIII Hospital, Bergamo, Italy
    • Xue, G.. Department of Biomedicine, University Hospital of Basel, Basel, Switzerland
    • Carobbio, A.. Department of Biomedicine, University Hospital of Basel, Basel, Switzerland
    • Nassini, R.. Unit of Clinical Pharmacology and Oncology, Department of Health Sciences, University of Florence, Florence
    • Baroni, G.. Division of Pathological Anatomy, Department of Surgery and Translational Medicine, University of Florence, Florence
    • Tamborini, E.. Experimental Molecular Pathology, Department of Pathology, National Cancer Institute, Milan
    • Cattaneo, L.. Division of Pathological Anatomy, Papa Giovanni XXIII Hospital, Bergamo
    • Audrito, V.. Human Genetics Foundation (HuGeF), Turin
    • Deaglio, S.. Human Genetics Foundation (HuGeF), Turin
    • Mandalà, M.. Unit of Medical Oncology, Department of Oncology and Hematology, Papa Giovanni XXIII Hospital, Bergamo
    Dokumententyp
    • Postprint
    Sprache
    • Englisch
    Veröffentlicht in
    • Annals of Oncology, 2015, vol. 26, no. 9, p. 1980-1987. Oxford University Press
    Andere elektronische Ausgabe
    OAI-PMH-ID
    • oai:doc.rero.ch:296992
    Summary
    In the present study, we have provided clinical evidence of the predictive and prognostic relevance of tumoral PD-L1 expression and density of immune cell infiltration in BRAFV600-mutated metastatic melanoma patients treated with BRAF inhibitors